Slide 1: Coloplast earnings conference call 9M 2021/22
Coloplast earnings conference call 9M 2021/22 Making life easier STRIVE25: SUSTAINABLE GROWTH LEADERSHIP Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voice & Respiratory Care
Slide 2: Forward-looking statements
Forward-looking statements The forward-looking statements contained in this presentation, including forecasts of sales and earnings performance, are not guarantees of future results and are subject to risks, uncertainties and assumptions that are difficult to predict. The forward-looking statements
Slide 3: Solid Q3 with 8% organic growth and an EBIT margin of 30%
Solid Q3 with 8% organic growth and an EBIT margin1 of 30%. FY 2021/22 financial guidance is unchanged REVENUE GROWTH Q3 2021/22 highlights Reported revenue (mDKK) Organic growth Reported growth • Organic growth of 8% and reported growth in DKK of 21%. Atos Medical contributed 9%- points to reported
Slide 4: Q3 organic growth of 8% was driven mostly by Chronic Care
Q3 organic growth of 8% was driven mostly by Chronic Care, with solid contribution from all regions, excluding China Q3 2021/22 revenue by business area Q3 2021/22 revenue by geography Business Reported revenue Q3 Organic growth Share of organic Geographic Reported revenue Q3 Organic growth Share of
Slide 5: 9M reported growth was up 15%, with positive impact from Atos acquisition
9M reported growth was up 15%, with ~5%-points positive impact from the Atos acquisition and ~3%-points impact from currencies 9M Revenue development (DKKm) Highlights • Reported revenue increased by DKK 2,194 million, or 15% vs. last year • 9M organic growth was 7% or DKK 972 million, driven by: 45
Slide 6: Reported EBIT margin of 31% in 9M reflecting increased commercial activity
Reported EBIT margin1 of 31% in 9M reflecting increased level of commercial activity and the Atos Medical acquisition 9M EBIT margin development before special items (%) Highlights • 9M gross margin was 69%, against 68% in 9M last year • Positive impact from operating leverage and the Atos Medical 0
Slide 7: FCF driven by solid underlying development in earnings, impacted by Atos Medical
FCF driven by solid underlying development in earnings, impacted by the Atos Medical acquisition FCF development Comments Highlights • Free cash flow was an outflow of DKK 8,399 million compared to an inflow of DKK 1,626 million in 9M 2020/21 98 99 98 93 • The decrease was mainly driven by an increa
Slide 8: FY 2021/22 guidance: Organic growth of 6-7% and EBIT margin around 31%
FY 2021/22 guidance: Organic growth of 6-7% and reported EBIT margin before special items around 31% GUIDANCE 2021/22 GUIDANCE (DKK)* KEY ASSUMPTIONS • Continued resumption of hospital activity across business areas • Chronic Care: continued improvement in growth in Europe, as a result of normalised
Slide 9: Page 9
Coloplast Group - Ostomy Care / Continence Care / Wound & Skin Care / Interventional Urology / Voice & Respiratory Care Page 9